Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689482 | 0.88 | MET (0.37) | CA12CA1CA9PREP | |
| SCHEMBL29736070 | 0.88 | MET (0.37) | CA12CA1CA9PREP | |
| SCHEMBL19698945 | 0.80 | CA12 (0.38) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29216000 | 0.80 | NR1H4 (0.54) | NR1H4HSD17B13 | |
| SCHEMBL30775154 | 0.80 | NR1H4 (0.54) | NR1H4HSD17B13 | |
| SCHEMBL30775155 | 0.79 | CA12 (0.37) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL19689521 | 0.79 | CA12 (0.37) | CA12CA1CA9PREPHSP90AA1 | |
| Hydrochloric Acid SCHEMBL29489583 | 0.78 | CA12 (0.36) | CA12CA1CA9PREPHSP90AA1 | |
| Hydrochloric Acid SCHEMBL19690213 | 0.78 | CA12 (0.36) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29139869 | 0.77 | NR1H4 (0.45) | CA12CA1CA9NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225473-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200255418-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225473-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | CA12 4742/4885CA1 4536/4885CA9 4854/4885 |
| US-20200255418-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4742/4885CA1 4536/4885CA9 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.